BeiGene Ltd ADR buy melinda
Start price
28.02.18
/
50%
€137.10
Target price
06.03.18
€140.71
Performance (%)
3.03%
End price
06.03.18
€141.25
Summary
This prediction ended on 06.03.18 with a price of €141.25. The BUY prediction by melinda finished with a performance of 3.03%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| BeiGene Ltd ADR | 2.778% | 2.778% | -10.303% | -51.316% |
| iShares Core DAX® | 0.611% | -2.723% | 14.325% | 14.359% |
| iShares Nasdaq 100 | -0.208% | 6.703% | 37.781% | 55.710% |
| iShares Nikkei 225® | 1.298% | 1.009% | 9.641% | 4.825% |
| iShares S&P 500 | 0.636% | 5.035% | 30.827% | 48.685% |
Comments by melinda for this prediction
In the thread Beigene Ltd ADR diskutieren
Biotechnologie und medizinische SecteurRecherche
Beigene kündigt Zulassung von Revlimid in China
27. Februar (Reuters) - Beigene Ltd :: BEIGENE REVLIMID KÜNDIGT DIE GENEHMIGUNG FÜR MYELOMA DIAGNOSE CHINE.BEIGENE LTD EBEN - REVLIMID WURDE VON DEN VERWALTUNGSRAT UND CHEMISCHE FOOD CHINA FÜR DIE BEHANDLUNG VON MYELOMA GENEHMIGT
Stopped prediction by melinda for BeiGene Ltd ADR
BeiGene Ltd ADR
Start price
Target price
Perf. (%)
€124.64
02.04.19
02.04.19
€250.00
04.11.21
04.11.21
158.35%
05.11.21
05.11.21
BeiGene Ltd ADR
Start price
Target price
Perf. (%)
€109.65
12.11.18
12.11.18
€144.32
28.11.18
28.11.18
19.77%
28.11.18
28.11.18